Ribociclib
Novartis
['breast']
 these landmark results will fundamentally change how we treat patients with stage ii and iii hr+/her2- early breast cancer who are in need of new, well-tolerated options that prevent their cancer from coming back, said the trial s lead investigator, dr. dennis j. slamon 
PR & Marketing Agency ✍🏻📺🎙🎧 Stephanie Gillis-Paulgaard +20 years in: PR | Marketing | Strategy | Branding | FREE CONTENT TIPSHEET⤵️